611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
General, Central Obesity Linked to Specific Breast Cancer RiskProton Pump Inhibitors Overused WorldwideWeight-Loss Surgery May Leave Some AnemicHealth Tip: Four Common Types Of AcneOne-Quarter of Lupus Patients Have Metabolic SyndromeKids' Colds Linked to Asthma, Lung Problems LaterMetabolomic Profiles Differ With Macular DegenerationExtended Thromboprophylaxis Safe, Effective After Liver SurgeryExercise May Stem Kidney Damage in Lupus PatientsMinorities Exposed to Dirtier Air, U.S. Study FindsDoctors Eye the Danger From 'Nerf' GunsHealth Tip: Preventing Food Allergies While Dining OutIt's a Food Allergy! Where's the School Nurse?Lower Mortality Risk Seen With Statin Use in Older MenSleep Quality, Duration Linked to CKD ProgressionSelena Gomez's Kidney Transplant Puts Lupus Center StageVision Problems Common in Babies Infected With ZikaSmoking, Poor Diet Lead Global Death CausesWhich Single Behavior Best Prevents High Blood Pressure?Traces of Tattoo May Reach the Lymph NodesVitamin D Deficiency Tied to Neuropathic Pain'Upside' to Diabetes Really Isn'tSemen Harbors Wide Range of VirusesHeath Tip: Contact Lenses Aren't Risk-FreeDiabetes Threatens Kidneys, Vision of Millions of AmericansNew Guideline Aims to Help Doctors Diagnose Head, Neck Masses'Microbiomes' May Hold Key to Kids' Ear InfectionsWarfarin, Rivaroxaban Similarly Safe, EffectiveHealth Tip: Leading Causes of Food PoisoningER Visits for These 3 Health Woes Don't Have to Happen'Modest at Best' Discriminatory Ability for CBC Test in InfantsDo E-Cigarettes Damage Blood Vessels?'Healthy' Obese Still Face Higher Heart RisksTake a Stand Against Sitting Too MuchGreater Height Tied to Higher Risk of Venous ThromboembolismZika Virus Preferentially Targets Glioblastoma Stem CellsBiomarkers Can Predict Rapid Drop in Renal Function in T2DMPeople Picking Up Infection From Pet Store Puppies' Poop: CDCHeath Tip: Getting Rid of Head LiceThe Health Risks of Long Work WeeksLupus Hits Certain Groups HarderSocioeconomic Conditions Affect Metabolic Syndrome RiskAirway Mucin Concentrations May Help Predict Chronic BronchitisCenter Surgical Volume Linked to LVAD Patient OutcomesGuinea Pigs Harbor a Hidden Health HazardHealth Tip: Antibiotic-Resistant BacteriaFor City Kids With Asthma, Nearby Green Space Is KeyThe Best Way to Diagnose a Food AllergyBudget Cuts Threaten Research on Antimicrobial ResistanceIntensive BP Control Associated With Increased CKD Risk
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Powerful New Cholesterol Med Won't Harm Memory, Easing Concerns

HealthDay News
by By Amy NortonHealthDay Reporter
Updated: Aug 16th 2017

new article illustration

WEDNESDAY, Aug. 16, 2017 (HealthDay News) -- Despite some early concerns, a new study suggests the powerful cholesterol drugs known as PCSK9 inhibitors may not cause memory problems or other mental symptoms.

The drugs, which include evolocumab (Repatha) and alirocumab (Praluent), were approved in the United States in 2015. That came after trials showed they can dramatically slash LDL cholesterol (the "bad" kind), including in people with a genetic condition that often causes premature heart disease.

But early findings also hinted at a potential side effect: cognitive problems such as memory lapses and confusion.

The risk was small, though, and it was not clear whether the drugs were actually causing the problems.

Enter the new study. It's the first to actually follow PCSK9 patients over time, looking for new memory problems or other cognitive issues, said lead researcher Dr. Robert Giugliano.

The study involved more than 1,200 patients who were randomly assigned to take either Repatha or a placebo. At the outset, patients took standard tests of memory, planning and other mental skills. They repeated those tests three times over the next two years.

The patients were also asked about any cognitive issues they'd noticed in daily life.

Overall, the study found, no differences surfaced between Repatha patients and those taking the placebo.

The findings should be "reassuring," said Giugliano, a heart disease specialist at Brigham and Women's Hospital in Boston.

Dr. Erin Michos, a cardiologist who was not involved in the study, agreed.

"I do think the findings should provide much reassurance to patients," said Michos, who is associate director of preventive cardiology at Johns Hopkins University in Baltimore.

Still, she said, the patients -- who were 63 years old, on average -- were typically followed for only 19 months.

"I am definitely interested in longer follow-up," Michos said. "We will need to see what happens after 10 years."

A five-year extension study is underway, Giugliano said. The research is being funded by Repatha maker Amgen, Inc.

For now, Michos said she feels "very comfortable" recommending PCSK9 inhibitors to certain "high-risk" patients who can benefit from them.

That includes people with familial hypercholesterolemia, a genetic condition that causes very high LDL and, often, early heart disease.

Some other patients might be candidates, too, Michos said. A prime example would be someone with a history of heart attack whose LDL is still higher than desired, despite treatment with standard cholesterol drugs.

Why would PCSK9 inhibitors have any effect on memory and thinking?

According to Michos, there have been theoretical concerns about slashing LDL too much. Cholesterol is a key component of cell membranes, including the sheath that covers brain cells.

But that worry, Michos noted, has been countered by a crucial fact: There is a "blood-brain barrier," and the brain makes its own cholesterol rather than pulling it from the blood.

So even a drastic drop in blood LDL, Giugliano said, should not affect the brain.

Plus, he added, the drug itself is "too big" to get past the blood-brain barrier and affect cholesterol production there.

There are some known downsides to PCSK9 inhibitors, however. They are taken by injection once a month or every two weeks, and people may have pain at the injection site, Giugliano said.

Then there's the price tag, Giugliano noted.

PCSK9 inhibitors cost more than $14,000 a year, according to the American College of Cardiology. Meanwhile, many statins are currently available as cheap generics.

Statins remain the go-to cholesterol drug, Michos stressed.

"I do everything possible to optimize patients on their statins first," she said.

Even when people think they are "statin intolerant" because of side effects, that's often not the case, Michos added.

Sometimes, she said, patients do well if they switch to a lower dose or a different statin.

In other cases, the statin may not be the culprit at all, Michos said. Many people have heard that statins can cause muscle pain, she noted, so they can be quick to blame their medication when body aches strike.

"Much of the time people attribute their muscle symptoms to their statins, when they are due to other causes, such as arthritis or vitamin D deficiency," Michos said.

The study was published Aug. 16 in the New England Journal of Medicine.

More information

The U.S. National Institutes of Health has more on treating high cholesterol.